USPTO Grants Patent for Idiopathic Pulmonary Fibrosis Treatment

The United States Patent and Trademark Office (USPTO) has issued patent US12582653B2 to BEIJING TIDE PHARMACEUTICAL CO., LTD. for a method of treating idiopathic pulmonary fibrosis. The patent claims a method involving the administration of a specific compound, represented by formula (I), or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotope-labeled compounds, metabolites, or prodrugs.

This patent grant signifies the protection of intellectual property related to a novel therapeutic approach for idiopathic pulmonary fibrosis. While not imposing direct compliance obligations on other entities, it is relevant for pharmaceutical companies and drug manufacturers engaged in research and development in this therapeutic area, as it may impact their freedom to operate or potential licensing opportunities.